NCT01041781

Clinical Trial Information

Trial Number: NCT01041781 (ClinicalTrials.gov)

Disease Type:

Lung, Mediastinal and Pleural Neoplasm - Non-Small Cell Lung Cancer

Trial Title:

A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer

Study ID:

CALGB-30801

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT01041781-D2	Dataset NCT01041781-D2-Dataset.csv (c30801_ae) is one of 2 datasets associated with PubMed ID 28489511. This dataset contains information that will allow you to reproduce the adverse events analysis. Due to further data cleaning subsequent to the JCO publication, there are slight discrepancies in the numbers of patients reporting various grade 3 adverse events from those reported in Table A3 in the publication.
NCT01041781-D1	Dataset NCT01041781-D1-Dataset.csv (c30801) is one of 2 datasets associated with PubMed ID 28489511. This dataset contains information that will allow you to reproduce the baseline characteristics table and primary analysis. In Table A5, there is a typo in the median number of OS months for Celecoxib patients with COX-2 >= 2. The correct numbers should be 15.73 (11.50-18.96) and they are the same as those present on this shared dataset.

Title

Description

NCT01041781-D2

Dataset NCT01041781-D2-Dataset.csv (c30801_ae) is one of 2 datasets associated with PubMed ID 28489511. This dataset contains information that will allow you to reproduce the adverse events analysis.

Due to further data cleaning subsequent to the JCO publication, there are slight discrepancies in the numbers of patients reporting various grade 3 adverse events from those reported in Table A3 in the publication.

NCT01041781-D1

Dataset NCT01041781-D1-Dataset.csv (c30801) is one of 2 datasets associated with PubMed ID 28489511. This dataset contains information that will allow you to reproduce the baseline characteristics table and primary analysis.

In Table A5, there is a typo in the median number of OS months for Celecoxib patients with COX-2 >= 2. The correct numbers should be 15.73 (11.50-18.96) and they are the same as those present on this shared dataset.

Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security

U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov

NIH…Turning Discovery Into Health^®